Polycythemia Vera Pv clinical trials

Explore recruiting polycythemia vera pv clinical trials.

Recruiting polycythemia vera pv studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Polycythemia Vera Pv trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

I3X-MC-JHTB: A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms

Spain, Germany, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients: the GIV-IN PV TRIAL

Hungary, Poland, Italy, Spain, Bulgaria, Croatia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms

France

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment

Germany, Czechia, Spain, Poland, Italy, Croatia +7 more

Phase II and Phase III (Integrated) EU CTIS Study details

Polycythemia Vera Pv trials by city

Polycythemia Vera Pv in Toronto Polycythemia Vera Pv in Vancouver Polycythemia Vera Pv in Montreal Polycythemia Vera Pv in Calgary Polycythemia Vera Pv in Edmonton Polycythemia Vera Pv in Ottawa Polycythemia Vera Pv in Winnipeg Polycythemia Vera Pv in Quebec City Polycythemia Vera Pv in Hamilton Polycythemia Vera Pv in Kitchener Polycythemia Vera Pv in London Polycythemia Vera Pv in Halifax Polycythemia Vera Pv in New York Polycythemia Vera Pv in Los Angeles Polycythemia Vera Pv in Chicago Polycythemia Vera Pv in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease